TE
ALLO icon

Tema ETFs’s Allogene Therapeutics ALLO Stock Holding History

Tema ETFs’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-219,072
Closed -$535K – 584
2026
Q1 		$535K Buy
+219,072
New +$439K 0.04% 352

Other funds holding ALLO

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
HDA
Harold Davidson & Associates Los Angeles, California $231M AUM 35.6% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CWMS
CFG Wealth Management Services Indianapolis, Indiana $107M AUM
WP
Westmount Partners Los Angeles, California $457M AUM 31.05% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
AIA
Arcadia Investment Advisors Eagle, Idaho $237M AUM 18.85% 1-Year Est. Return

Tema ETFs's ALLO Position: Q2 2026 in Review

Tema ETFs sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 219,072 shares — an estimated $535K sold.

Tema ETFs first reported a position in ALLO in Q1 2026 and held it in 1 quarter. The position peaked at $535K in Q1 2026. 10 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Tema ETFs reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Tema ETFs sold 219,072 Allogene Therapeutics shares in Q2 2026, an estimated $535K.
  • Tema ETFs first reported a position in Allogene Therapeutics in Q1 2026 and held it in 1 quarter.
  • Tema ETFs's Allogene Therapeutics position peaked at $535K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Tema ETFs's 13F filing for Q2 2026, filed 10 Jul 2026.